HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma

Oncology Letters

Volumn 6, Issue 1, 2013, Pages 13-18

  Huang, Jun Xing ^a   Zhao, Kun ^a   Lin, Mei ^a   Wang, Qi ^a   Xiao, Wei ^a   Lin, Mao Song ^a   Yu, Hong ^a   Chen, Ping ^a   Qian, Rong Yu ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Esophageal cancer; Fluorescence in situ hybridization; Gastric cancer; Human epidermal growth factor receptor 2 gene

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR 2 GENE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL CARCINOMA; GENE; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; STOMACH CANCER; TUMOR DIFFERENTIATION;

EID: 84878330019     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1348     Document Type: Article

References (35)

1. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. Liakakos T, Katsios C and Roukos DH: Gastroesophageal junction carcinoma multimodal treatment: standards, debate and new therapeutic options. Expert Rev Gastroenterol Hepatol 5: 1-4, 2011.
4. Ilson DH: Esophageal cancer chemotherapy: recent advances. Gastrointest Cancer Res 2: 85-92, 2008.
5. Ku GY and Ilson DH: Esophageal cancer: adjuvant therapy. Cancer J 13: 162-167, 2007.
6. Okines AF and Cunningham D: Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer. Therap Adv Gastroenterol 5: 301-318, 2012.
7. Dai GH, Shi Y, Chen L, Lv YL and Zhong M: Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression. Hepatogastroenterology 59: 2439-2444, 2012.
8. Hicks DG and Whitney-Miller C: HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge. Appl Immunohistochem Mol Morphol 19: 506-508, 2011.
9. Lordick F: Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer. Future Oncol 7: 187-199, 2011.
10. Reichelt U, Duesedau P, Tsourlakis MCh, et al: Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 20: 120-129, 2007.
11. Gabbert HE, Nakamura Y, Shimoda T, Field JK, Hainaut P and Inoue H: Squamous cell carcinoma of the oesophagus. In: World Health Organization Classification of Tumors. Hamilton SR and Aaltonen LA (eds.) 1st edition. IARC Press, Lyon, pp 16-17, 2000.
12. Huang J: Esophageal cancer. In: Manual of Medical Oncology. Sun Y and Shi YK (eds). 5th edition. The People's Medical Publishing House, Beijing, pp466-475, 2007.
13. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145, 2007.
14. Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434, 2007.
15. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
16. Koltz BR, Hicks DG and Whitney-Miller CL: HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options. Biotech Histochem 87: 40-45, 2012.
17. Sato-Kuwabara Y, Neves JI, Fregnani JH, Sallum RA and Soares FA: Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. BMC Cancer 9: 6, 2009.
18. Wei Q, Chen L, Sheng L, Nordgren H, Wester K and Carlsson J: EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol 31: 493-499, 2007.
19. Wu D, Xu J, Yu G, et al: Expression status of fatty acid synthase (FAS) but not HER2 is correlated with the differentiation grade and prognosis of esophageal carcinoma. Hepatogastroenterology: Jun 18, 2012 (Epub ahead of print).
20. Yoon HH, Shi Q, Sukov WR, et al: Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 18: 546-554, 2012.
21. Zhan N, Dong WG, Tang YF, Wang ZS and Xiong CL: Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma. Med Oncol 29: 933-940, 2012.
22. Varshney D, Zhou YY, Geller SA and Alsabeh R: Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas by comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol 121: 70-77, 2004.
23. Ross JS: Point: Fluorescence in situ hybridization is the preferred approach over immunohistochemistry for determining HER2 status. Clin Chem 57: 980-982, 2011.
24. Pazo Cid RA and Antón A: Advanced HER2-positive gastric cancer: Current and future targeted therapies. Crit Rev Oncol Hematol 85: 350-362, 2013.
25. Terashima M, Kitada K, Ochiai A, et al: Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 18: 5992-6000, 2012.
26. Shitara K, Yatabe Y, Matsuo K, et al: Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. Gastric Cancer: Jul 14, 2012 (Epub ahead of print).
27. Kim JW, Im SA, Kim M, et al: The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen. Anticancer Res 32: 1547-1553, 2012.
28. Barros-Silva JD, Leitão D, Afonso L, et al: Association of ERBB2 gene status with histopathological parameters and disease specific survival in gastric carcinoma patients. Br J Cancer 100: 487-493, 2009.
29. Rüschoff J: Adenocarcinoma of the GEJ: gastric or oesophageal cancer? Recent Results Cancer Res 196: 107-113, 2012.
30. Suh YS, Han DS, Kong SH, et al: Should adenocarcinoma of the esophagogastric junction be classified as esophageal cancer? A comparative analysis according to the seventh AJCC TNM classification. Ann Surg 255: 908-915, 2012.
31. Lorenzen S and Lordick F: How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer? Curr Opin Oncol 23: 396-402, 2011.
32. Fassan M, Ludwig K, Pizzi M, et al: Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas. Hum Pathol 43: 1206-1212, 2012.
33. Wainberg ZA, Lin LS, DiCarlo B, et al: Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br J Cancer 105: 760-765, 2011.
34. Thompson SK, Sullivan TR, Davies R and Ruszkiewicz AR: Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. Ann Surg Oncol 18: 2010-2017, 2011.
35. Grávalos C, Gómez-Martín C, Rivera F, Alés I, et al: Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol 13: 179-184, 2011.